Last reviewed · How we verify
NCT05459051: ORBITA-FIRE
Finding the Invasive Haemodynamic Threshold for Symptom Relief in Stable Angina
trial testing Rest-angina physiological assessment in Stable Angina in 58 participants. Status unknown.
8 April 2025
Quick facts
| Lead sponsor | Imperial College London |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 58 |
| Start date | 1 September 2022 |
| Primary completion | 8 April 2025 |
| Estimated completion | 8 April 2025 |
| Sites | 6 locations across United Kingdom |
Drugs / interventions tested
- Rest-angina physiological assessment
- Exercise-angina physiological assessment
Conditions studied
- Stable Angina — all drugs for Stable Angina →
Sponsor
Imperial College London
Who can join
18 and older, any sex, with Stable Angina. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
ORBITA-FIRE is a randomised, double-blinded, placebo controlled experimental study that will identify the fractional flow reserve (FFR) and non-hyperemic pressure ratio (NHPR) thresholds that correlate with symptoms of angina for 58 patients measured invasively under experimental conditions.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, et al · · 2023 · cited 147× · PMID 38015442 · DOI 10.1056/nejmoa2310610 -
A Placebo-Controlled Trial of PCI for Stable Angina.
Sherrod CF, O'Keefe EL, Ikemura N. · · 2024 · PMID 38507761 · DOI 10.1056/nejmc2400751
Verify or expand the search:
- PubMed search for NCT05459051
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stable Angina
Currently open trials in the same condition.
- NCT06436092 — Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry) · recruiting
- NCT05972070 — Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence · recruiting
- NCT05865600 — Perfusion Estimation For Optimal Treatment Strategy in Chronic Coronary Syndrome · NA · recruiting
- NCT05230446 — PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlus · NA · recruiting
- NCT05255705 — Barts Revascularisation Registry · recruiting
Other Imperial College London trials
Trials by the same sponsor.
- NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
- NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
- NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
- NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
- NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05459051 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imperial College London
- Last refreshed: 6 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05459051.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing